RITUXIMAB IN SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS

被引:0
作者
Her, M. [1 ]
Park, J. [2 ]
机构
[1] Inje Univ, Dept Internal Med, Haeundae Paik Hosp, Busan, South Korea
[2] Busan Hosp, Dept Internal Med, Vet Hlth Serv, Busan, South Korea
关键词
Lungs; biological DMARD; Systematic review; Comorbidities;
D O I
10.1136/annrheumdis-2025-eular.B684
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ABS1093
引用
收藏
页数:2
相关论文
共 2 条
[1]   Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease [J].
Ebata, Satoshi ;
Yoshizaki, Ayumi ;
Fukasawa, Takemichi ;
Miura, Shunsuke ;
Takahashi, Takehiro ;
Sumida, Hayakazu ;
Asano, Yoshihide ;
Sato, Shinichi .
JOURNAL OF DERMATOLOGY, 2019, 46 (11) :1006-1013
[2]   Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group [J].
Jordan, Suzana ;
Distler, Joerg H. W. ;
Maurer, Britta ;
Huscher, Doerte ;
van Laar, Jacob M. ;
Allanore, Yannick ;
Distler, Oliver .
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (06) :1188-1194